Last Updated:
10 Mar 2026, 03:29:50 PM (IST)
Par Drugs and Chemicals Limited
NSE: PAR
NSE
92.87
2.70 (2.99%)
Prev Close
90.17
Open Price
95.48
Volume
4,453
Today Low / High
91.31 / 95.48
52 WK Low / High
81.01 / 122.43
Range
88 - 98
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 92.87, with a change of 2.7 (2.99434%). The expected target range on the NSE is between 88 - 98. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Par Drugs and Chemicals Limited Graph
Par Drugs and Chemicals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Par Drugs and Chemicals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 92.87, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 92.87 | 93.80 | 84.42 - 103.18 |
| 94.73 | 75.78 - 113.67 | ||
| 95.66 | 66.96 - 124.35 | ||
| Bearish Scenario | 92.87 | 91.94 | 82.75 - 101.14 |
| 91.01 | 72.81 - 109.22 | ||
| 90.08 | 63.06 - 117.11 |
Overview of Par Drugs and Chemicals Limited
ISIN
INE04LG01015
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
20,681
Market Cap
1,132,395,651
Last Dividend
0
Official Website
IPO Date
2019-05-30
DCF Diff
-128.11
DCF
227
Financial Ratios Every Investor Needs
Stock Dividend of PAR
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-11-22 | November 22, 21 | 1.25 | 1.25 | 2021-11-23 | 2021-12-09 | |
| 2020-07-10 | July 10, 20 | 0.625 | 1.25 | 2020-07-13 | 2020-08-20 | |
| 2019-11-22 | November 22, 19 | 0.625 | 1.25 | 2019-11-25 | 2019-12-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 100.97 Cr | 38.13 Cr | 62.84 Cr | 0.6224 | 0.18 Cr | 0.00 Cr | 16.02 Cr | 13.36 Cr | 10.86 | 19.50 Cr | 0.1323 |
| 2024-03-31 | 95.64 Cr | 34.65 Cr | 60.99 Cr | 0.6377 | 0.11 Cr | 1.64 Cr | 55.16 Cr | 14.50 Cr | 11.78 | 22.95 Cr | 0.1516 |
| 2023-03-31 | 95.10 Cr | 66.40 Cr | 28.69 Cr | 0.3017 | 0.10 Cr | 1.24 Cr | 14.56 Cr | 11.33 Cr | 9.21 | 18.45 Cr | 0.1192 |
| 2022-03-31 | 74.61 Cr | 49.86 Cr | 24.34 Cr | 0.3262 | 0.01 Cr | 1.46 Cr | 12.66 Cr | 9.21 Cr | 7.49 | 16.36 Cr | 0.1235 |
| 2021-03-31 | 59.88 Cr | 37.44 Cr | 22.44 Cr | 0.3748 | 0.10 Cr | 0.79 Cr | 13.19 Cr | 11.61 Cr | 9.45 | 18.19 Cr | 0.1939 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 27.58 Cr | 119.39 Cr | 20.42 Cr | 98.9749 Cr | 0.00 Cr | -27.58 Cr | 6.11 Cr | 38.91 Cr | 0.00 Cr | 0.00 Cr | 25.07 Cr | 16.5685 Cr |
| 2024-03-31 | 36.65 Cr | 101.61 Cr | 15.98 Cr | 85.6320 Cr | 0.00 Cr | -36.65 Cr | 4.42 Cr | 41.33 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 12.4391 Cr |
| 2023-03-31 | 22.24 Cr | 88.87 Cr | 17.63 Cr | 71.2383 Cr | 0.00 Cr | -22.24 Cr | 5.97 Cr | 38.69 Cr | 0.06 Cr | 0.00 Cr | 0.01 Cr | 13.9894 Cr |
| 2022-03-31 | 16.21 Cr | 78.69 Cr | 18.81 Cr | 59.8772 Cr | 0.00 Cr | -16.21 Cr | 5.50 Cr | 34.35 Cr | 0.01 Cr | 0.00 Cr | 0.01 Cr | 14.8574 Cr |
| 2021-03-31 | 21.16 Cr | 76.38 Cr | 24.17 Cr | 52.2145 Cr | 8.32 Cr | -12.84 Cr | 3.89 Cr | 34.37 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 15.9792 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 16.1602 Cr | -25.2370 Cr | 0.0000 Cr | 14.9336 Cr | -9.0767 Cr | 27.5772 Cr | -1.2266 Cr | 13.3579 Cr | 0.0000 Cr | 0.0000 Cr | -1.9289 Cr |
| 2024-03-31 | 20.2489 Cr | -5.8381 Cr | 0.0000 Cr | 14.1686 Cr | 14.4109 Cr | 36.6539 Cr | -6.0803 Cr | 14.5010 Cr | 0.0000 Cr | 0.0000 Cr | 1.2019 Cr |
| 2023-03-31 | 13.3771 Cr | -7.3381 Cr | -0.0024 Cr | 5.7435 Cr | 6.0366 Cr | 22.2430 Cr | -7.6336 Cr | 15.0792 Cr | 0.0000 Cr | 0.0000 Cr | -0.6662 Cr |
| 2022-03-31 | 7.6152 Cr | -3.0184 Cr | -9.5542 Cr | 4.4129 Cr | -4.9574 Cr | 16.2064 Cr | -3.2023 Cr | 12.7032 Cr | -7.6396 Cr | -1.5381 Cr | -1.7160 Cr |
| 2021-03-31 | 12.0851 Cr | 0.0507 Cr | 1.6489 Cr | 7.0359 Cr | 13.7847 Cr | 21.1638 Cr | -5.0491 Cr | 14.7261 Cr | 3.0206 Cr | -0.7690 Cr | -0.0799 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 29.34 Cr | 14.74 Cr | 14.60 Cr | 0.4978 | 5.13 Cr | 4.80 Cr | 3.90 | 6.06 Cr | 0.1635 |
| 2025-09-30 | 28.66 Cr | 10.72 Cr | 17.94 Cr | 0.6258 | 5.13 Cr | 4.13 Cr | 3.36 | 6.55 Cr | 0.1441 |
| 2025-06-30 | 26.05 Cr | 11.34 Cr | 14.71 Cr | 0.5648 | 2.66 Cr | 3.33 Cr | 2.70 | 5.40 Cr | 0.1278 |
| 2025-03-31 | 22.33 Cr | 9.78 Cr | 12.55 Cr | 0.5621 | 1.51 Cr | 1.65 Cr | 1.34 | 2.42 Cr | 0.0739 |
| 2024-12-31 | 21.38 Cr | 8.81 Cr | 12.57 Cr | 0.5880 | 0.51 Cr | 0.58 Cr | 0.47 | 1.70 Cr | 0.0270 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 33.86 Cr | 0.00 Cr | 33.86 Cr | 17.72 Cr | 5.28 Cr | 62.43 Cr | 37.77 Cr | 127.52 Cr | 21.09 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 27.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -98.97 Cr |
| 2025-03-31 | 27.58 Cr | 0.00 Cr | 27.58 Cr | 16.81 Cr | 6.11 Cr | 54.86 Cr | 38.91 Cr | 119.39 Cr | 20.42 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 18.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -96.76 Cr |
| 2024-09-30 | 18.78 Cr | 0.00 Cr | 18.78 Cr | 22.98 Cr | 4.93 Cr | 49.06 Cr | 40.13 Cr | 115.65 Cr | 18.89 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 3.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 1.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 8.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 2.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2021-04-27 | April 27, 21 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chief Financial Officer
Chintan Pratapbhai Chauhan
Gender: male
Year Born: 1983
Chairman of the Board & MD
Falgun Vallabhbhai Savani
Gender: male
Year Born: 1974
Chief Executive Officer & Executive Director
Jignesh Vallabhbhai Savani
Gender: male
Year Born: 1977
Company Secretary & Compliance Officer
Sanket Bhupendrabhai Trivedi
Gender: male
Year Born: 1990
FAQs about Par Drugs and Chemicals Limited
Who is the CEO of the company?
The CEO is Jignesh Vallabhbhai Savani.
What is the current market price of the stock?
The current price is ₹92.03.
What is the 52-week price range?
The range is ₹81.01-122.43.
What is the market capitalization of the company?
The market capitalization is ₹113.24 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 8.14.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Par Drugs and Chemicals Limited (ISIN: INE04LG01015) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹113.24 crores and an average daily volume of 20,681 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.